Enter assignee name

CIPO Patents = 1

EPO Patents = 5

Trademarks = 2

Forward Citations = 110

Loading Chart...

4 inventors (with patents filed for the assignee):

Hiroaki Shizuya (20 out of 24 patents)

Larry L Green (20 out of 71 patents)

Dana Duey (2 out of 3 patents)

4. John Lippincott (2 out of 9 patents)

22 patents: Sort by Forward Citations

1. 11753478 - Anti-CD115 antibodies (2023-09-12),

2. 11352444 - Genetic engineering of non-human animals for the production of chimeric antibodies (2022-06-07),

3. 11242409 - Genetic engineering of non-human animals for the production of chimeric antibodies (2022-02-08),

4. 11220555 - Genetic engineering of non-human animals for the production of chimeric antibodies (2022-01-11),

5. 11104744 - Genetic engineering of non-human animals for the production of chimeric antibodies (2021-08-31),

6. 11104743 - Genetic engineering of non-human animals for the production of chimeric antibodies (2021-08-31),

7. 10836832 - Genetic engineering of non-human animals for the production of chimeric antibodies (2020-11-17),

8. 10829564 - Genetic engineering of non-human animals for the production of chimeric antibodies (2020-11-10),

9. 10759861 - Anti-CD115 antibodies (2020-09-01),

10. 10662255 - Genetic engineering of non-human animals for the production of chimeric antibodies (2020-05-26),

11. 10638736 - Non-human mammals for the production of chimeric antibodies (2020-05-05),

12. 10626188 - Genetic engineering of non-human animals for the production of chimeric antibodies (2020-04-21),

13. 10618977 - Genetic engineering of non-human animals for the production of chimeric antibodies (2020-04-14),

14. 10604587 - Genetic engineering of non-human animals for the production of chimeric antibodies (2020-03-31),

15. 10575504 - Non-human mammals for the production of chimeric antibodies (2020-03-03),

Ablexis is a biopharmaceutical company dedicated to the discovery and development of next-generation antibody therapies. Leveraging its proprietary AlivaMab Mouse platform, Ablexis enables partners to rapidly generate high-quality, diverse antibody leads for therapeutic applications in a variety of disease areas. With a focus on speed, precision, and efficiency, Ablexis supports its partners in advancing innovative antibody drugs that have the potential to transform patient lives.

This text is generated by artificial intelligence and may not be accurate.